...
首页> 外文期刊>Drug discovery today >Continuous manufacturing via hot-melt extrusion and scale up: regulatory matters
【24h】

Continuous manufacturing via hot-melt extrusion and scale up: regulatory matters

机译:通过热熔挤压和扩大的连续制造:监管事项

获取原文
获取原文并翻译 | 示例
           

摘要

Currently, because globalization, the pharmaceutical industry is facing enormous challenges to comply with regulatory matters. Reduced patent life and overall decreased profitability of newly discovered drugs are also forcing the pharmaceutical industry to shorten the drug development time with maximum throughput. Therefore, continuous manufacturing (CM) processes via hot melt extrusion (HME) can be a promising alternative for achieving these goals. HME offers solvent-free green technology with a process that is easy to scale up. Moreover, CM provides better product quality assurance compared with batch processes, with fewer labor costs and shorter time to development. In this review, we primarily focus on various aspects of CM and the emerging application of HME to bridge the current manufacturing gap in pharmaceutical sphere.
机译:目前,由于全球化,制药行业面临巨大挑战,以遵守监管事项。 降低的专利生命和全面降低的新发现药物的盈利能力也强迫制药行业缩短了最大产量的药物开发时间。 因此,通过热熔挤出(HME)的连续制造(CM)方法可以是实现这些目标的有希望的替代方案。 HME提供无溶剂绿色技术,具有易于扩展的过程。 此外,CM与批处理流程相比提供了更好的产品质量保证,劳动力成本较少,发展时间较短。 在本综述中,我们主要专注于CM的各个方面和HME的新兴应用,以弥合药物球体的当前制造空间。

著录项

  • 来源
    《Drug discovery today》 |2017年第2期|共12页
  • 作者单位

    Univ Sussex Sch Life Sci Pharmaceut Res Lab Arundel Bldg Brighton BN1 9QJ E Sussex England;

    Univ Sussex Sch Life Sci Pharmaceut Res Lab Arundel Bldg Brighton BN1 9QJ E Sussex England;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号